Feb 03, 2022 8:00am EST Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis
Jan 26, 2022 8:00am EST Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments
Dec 21, 2021 8:00am EST Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
Nov 29, 2021 5:45pm EST Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Nov 24, 2021 8:52am EST Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
Nov 23, 2021 8:00am EST Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
Nov 17, 2021 8:00am EST Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint
Nov 11, 2021 8:00am EST Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
Nov 09, 2021 8:00am EST Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
